Search results
Found 6798 matches for
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
Population, Global, and Public Health
Population and global health research generates evidence that reliably answers important questions about human health.